Participant flow

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) · Source last updated 2025-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Adult participants received pembrolizumab (MK-3475) 200 mg or pediatric participants received 2 mg/kg (up to 200 mg) on Day 1 of each 3-week cycle (Q3W) intravenously (IV), for up to 35 administrations (approximately 2 years).

   id

   FG000

   title

   Pembrolizumab 200 mg

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         31

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         23

      type

      Sponsor Decision

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Parent/Guardian

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         55

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         55

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Participants of at least 12 years of age with advanced Merkel cell carcinoma (MCC) were recruited to evaluate the safety and efficacy of Pembrolizumab (MK-3475) as first-line therapy.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice